Physician profile
Logan Haney
NPI 1760243687
$1,677.26
in general payments reported to CMS, 2019-2025
23 companies · $899 in 2025
The $899 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $778 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $306.12 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $167.12 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $164.85 | 2024-2025 | |
| Grifols USA, LLC | $162.17 | 2024-2025 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $136.14 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $71.64 | 2024-2025 | Trelegy Ellipta |
| Lundbeck LLC | $68.93 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $59.65 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $58.59 | 2024 | |
| Antares Pharma, INC. | $57.19 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $52.85 | 2025 | |
| Phathom Pharmaceuticals, INC. | $49.00 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $41.82 | 2025 | Eliquis |
| Viatris Specialty LLC | $40.03 | 2025 | Yupelri |
| Radius Health, INC. | $36.11 | 2024 | Tymlos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.06 | 2024-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Axsome Therapeutics, INC. | $34.67 | 2025 | Auvelity |
| Exact Sciences Corporation | $33.24 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $30.29 | 2024-2025 | Otezla, Repatha, Prolia |
| Mylan Specialty L.P. | $23.81 | 2024 | Yupelri |
| Abbott Laboratories | $17.51 | 2025 | Freestyle Libre 3 |
| Tolmar, INC. | $16.59 | 2025 | Jatenzo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.88 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.